Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8209	Companies
109602	Keywords
51697	Articles
60327	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 07/26/2024 at 10:59, 3 months 9 days ago

FYB202 Biosimilar to Stelara Receives Positive CHMP Opinion from EMA

Biosimilar Formycon FYB202 CHMP EMA
PRESS RELEASE

published on 07/26/2024 at 10:54, 3 months 9 days ago

EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Formycon AG's biosimilar candidate FYB202 (Ustekinumab) for Stelara® receives a positive opinion from EMA's CHMP, recommended for EU approval for treating severe inflammatory diseases

Formycon AG Biosimilar FYB202 CHMP EMA
BRIEF

published on 07/01/2024 at 06:55, 4 months 4 days ago

Formycon Receives FDA Approval for Aflibercept Biosimilar

FDA Approval Biosimilar Formycon Retinal Diseases Ophthalmic Therapies
BRIEF

published on 07/01/2024 at 06:55, 4 months 4 days ago

Formycon reçoit l'approbation de la FDA pour le biosimilaire Aflibercept

Approbation De La FDA Formycon Biosimilaire Maladies De La Rétine Thérapies Ophtalmiques
PRESS RELEASE

published on 07/01/2024 at 06:50, 4 months 4 days ago

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Formycon receives FDA approval for FYB203/AHZANTIVE(R) (aflibercept-mrbb), a biosimilar to Eylea(R). The approval highlights Formycon's expertise and commitment to providing effective and affordable biosimilar therapies for retinal diseases.

FDA Approval Biosimilar Formycon Eylea Retinal Diseases
BRIEF

published on 06/28/2024 at 23:55, 4 months 6 days ago

FDA Approves Biosimilar FYB203/AHZANTIVE® for Retinal Diseases

FDA Approval Biosimilar Eylea Retinal Diseases Treatment Approval
BRIEF

published on 06/28/2024 at 23:55, 4 months 6 days ago

La FDA approuve le biosimilaire FYB203/AHZANTIVE® pour les maladies rétiniennes

Approbation De La FDA Biosimilaire Eylea Maladies De La Rétine Approbation Du Traitement
PRESS RELEASE

published on 06/28/2024 at 23:50, 4 months 6 days ago

EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
FDA grants approval for Eylea biosimilar FYB203/AHZANTIVE by Formycon AG and Klinge Biopharma GmbH. Biosimilar approved for nAMD and other retinal diseases

FDA Approval Retinal Diseases Eylea Biosimilar FYB203/AHZANTIVE Neovascular Age-Related Macular Degeneration
BRIEF

published on 06/13/2024 at 15:35, 4 months 21 days ago

Formycon annonce les résultats de l'AGA et les changements au conseil d'administration

Actionnaires Exercice 2023 Conseil De Surveillance AGA Formycon
BRIEF

published on 06/13/2024 at 15:35, 4 months 21 days ago

Formycon Announces AGM Results and Board Changes

Shareholders 2023 Financial Year Supervisory Board AGM Formycon

Accesswire

Published on 11/05/2024 at 09:15, 1 hour 3 minutes ago

Troy Minerals Targets Restart of Drilling at Tsagaan Zalaa
Published on 11/05/2024 at 09:05, 1 hour 13 minutes ago

Omega Pacific Adds John Williamson as Independent Director
Published on 11/05/2024 at 08:00, 2 hours 18 minutes ago

Touchstone Exploration Announces Execution of Licence for Rio Claro Block
Published on 11/05/2024 at 08:00, 2 hours 18 minutes ago

Argo Blockchain PLC Announces October Operational Update
Published on 11/05/2024 at 03:30, 6 hours 48 minutes ago

CORRECTION: Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses

View all ACCESSWIRE

EQS Group

Published on 11/05/2024 at 10:07, 11 minutes ago

CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025
Published on 11/05/2024 at 10:02, 16 minutes ago

EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
Published on 11/05/2024 at 10:00, 18 minutes ago

Future KWS Executive Board team is finalized – Dr. Jörn Andreas and Sebastian Talg appointed
Published on 11/05/2024 at 09:02, 1 hour 16 minutes ago

Original-Research: THE NAGA GROUP AG (von NuWays AG): Buy
Published on 11/05/2024 at 09:01, 1 hour 17 minutes ago

Original-Research: Marley Spoon Group SE (von NuWays AG): Buy

Les Echos

Published on 11/05/2024 at 09:58, 20 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 31 octobre 2024
Published on 11/05/2024 at 09:27, 51 minutes ago

Mersen: Number of shares and voting rights as of October 31, 2024
Published on 11/05/2024 at 09:27, 51 minutes ago

Mersen : nombre d'actions et de droits de vote au 31 octobre 2024
Published on 11/05/2024 at 08:30, 1 hour 48 minutes ago

Cie du Bois Sauvage: Terugkoop van eigen aandelen – Week van 28/10/2024 tot 01/11/2024
Published on 11/05/2024 at 08:30, 1 hour 48 minutes ago

Cie du Bois Sauvage : Rachat d’actions propres – semaine du 28/10/2024 au 01/11/2024

View all LES ECHOS COMFI WIRE